Recent Updates
Recently added Catalysts
ANIP Positive Sentiment

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

Key Takeaway: ANI Pharmaceuticals announced that CEO Nikhil Lalwani and the executive team will present at upcoming investor conferences. The company aims to enhance its visibility and engagement with investors. Live and archived webcasts will be accessible on their website, promoting transparency and communication.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company will present at multiple investor conferences.
  • Leadership team will engage in discussions.
  • Webcasts will be available for wider access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
1.9%
average across 4 past catalysts
Lead asset
Fluocinolone Acetonide/Medidur
Phase 3 · Diabetic Macular Edema

Full Press Release Details

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:
Event Guggenheim 3rd Annual Healthcare Innovation Conference
Date Tuesday, November 10, 2026
Time 1:30 p.m. ET
Webcast Click here
Event 2026 Jefferies Global Healthcare Conference in London
Date Tuesday, November 17, 2026
Time 9:30 a.m. GMT
Webcast Click here
The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com

Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.

Frequently Asked Questions

Who will present at the investor conferences?

CEO Nikhil Lalwani and the executive leadership team will present.

Where can I access the webcasts?

Webcasts will be available on ANI's website in the Investors section.

What is ANI Pharmaceuticals focused on?

The company develops therapeutics in rare diseases and generics.

When are the investor conferences scheduled?

The specific dates for the conferences are not mentioned.

Last updated: Nov 3, 2026